Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.

ABSTRACT:

Purpose

To assess the immunomodulatory and clinical effects of lenalidomide with standard treatment of gemcitabine in patients with advanced pancreatic cancer.

Patients and methods

Patients with advanced pancreatic cancer were treated in first line with lenalidomide orally for 21 days of a 28 days cycle and the standard regimen for gemcitabine. In Part I, which we previously have reported, the dose of lenalidomide was defined (n = 12). In Part II, every other consecutive patient was treated with either lenalidomide (Group A, n = 11) or gemcitabine (Group B, n = 10) during cycle 1. From cycle 2 on, all Part II patients received the combination.

Results

A significant decrease in the proliferative response of peripheral blood mononuclear cells and the frequency of DCs we

SUBMITTER: Ullenhag GJ 

PROVIDER: S-EPMC5242484 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature